<p> Dr. Brian Callaghan discusses the AAN’s comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug for Alzheimer’s disease.</p>

Dr. Brian Callaghan discusses the AAN’s comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug for Alzheimer’s disease.

Cost-Effectiveness of Aducanumab

The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, Ph.D., FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.

Share Cost-Effectiveness of Aducanumab

Sign up to save your podcasts

Cost-Effectiveness of Aducanumab

Cost-Effectiveness of Aducanumab

More shows like Neurology Minute

JAMA Editors' Summary

Neurology® Podcast

NEJM This Week

Practical Neurology Podcast

JAMA Clinical Reviews

JAMA Neurology Author Interviews

JAMA Medical News

Neurology Today in 5

Annals On Call Podcast

Navigating Neuropsychology

The Clinical Problem Solvers

Harrison's PodClass: Internal Medicine Cases and Board Prep

Neurology Exam Prep Podcast

The Curious Clinicians

Continuum Audio